review Open AccessTop 1% cited

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

Annals of Oncology · 2019 · Vol. 30(8) · pp. 1232–1243

Claudio Luchini(University of Verona)Frédéric Bibeau(Université de Caen Normandie)M. Ligtenberg(Radboud University Nijmegen)Naveena Singh(Barts Health NHS Trust)Alessia Nottegar(Ospedale San Bortolo)Tjalling Bosse(Leiden University)Robert E. Miller(University College London)Nadeem Riaz(Memorial Sloan Kettering Cancer Center)J-Y Douillard(European Society for Medical Oncology)Fabrice André✉(Institut Gustave Roussy)Aldo Scarpa(University of Verona)

View via DOI Full-text PDF

Abstract

This ESMO initiative is a response to the urgent questions raised by the growing success of immunotherapy and provides also important insights on the relationships between MSI, TMB and PD-1/PD-L1.

Genetic factors in colorectal cancer Cancer Genomics and Diagnostics Lung Cancer Treatments and MutationsMicrosatellite instabilityMSH6MSH2MLH1DNA mismatch repairPMS2MedicineLynch syndromeComputational biologyCancer

MeSH terms

Antineoplastic Agents, ImmunologicalDNA Mutational AnalysisEuropean UnionGenetic TestingHumansImmunohistochemistryMedical OncologyMutationNeoplasmsSocieties, MedicalBiomarkers, TumorPractice Guidelines as TopicPatient SelectionMicrosatellite InstabilityDNA Mismatch Repair